{"parse":{"title":"Orphan drug","pageid":395889,"revid":858360579,"text":{"*":"<div class=\"mw-parser-output\"><p>An <b>orphan drug</b> is a <a href=\"/wiki/Medication\" title=\"Medication\">pharmaceutical agent</a> that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an <a href=\"/wiki/Orphan_disease\" class=\"mw-redirect\" title=\"Orphan disease\">orphan disease</a>.\n</p><p>The assignment of <b>orphan status</b> to a disease and to any drugs developed to treat it is a matter of <a href=\"/wiki/Public_policy_(law)\" class=\"mw-redirect\" title=\"Public policy (law)\">public policy</a> in many countries and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug <a href=\"/wiki/Medical_research\" title=\"Medical research\">research and development</a>.<sup id=\"cite_ref-Executive_1-0\" class=\"reference\"><a href=\"#cite_note-Executive-1\">&#91;1&#93;</a></sup>\n</p><p>In the US and the EU, it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as an extended period of exclusivity, a time during which that company is the only one allowed to market the orphan drug\u2014all intended to encourage the development of those drugs which might otherwise lack a sufficient <a href=\"/wiki/Profit_motive\" title=\"Profit motive\">profit motive</a> and market to attract companies' research budgets and personnel.<sup id=\"cite_ref-EvaluatePharma_2014_2-0\" class=\"reference\"><a href=\"#cite_note-EvaluatePharma_2014-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-Daly_2002_3-0\" class=\"reference\"><a href=\"#cite_note-Daly_2002-3\">&#91;3&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Definition\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Definition</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Global_statistics\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Global statistics</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Effect_on_investment,_sales_and_profit\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Effect on investment, sales and profit</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#Legislation\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Legislation</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-5\"><a href=\"#United_States\"><span class=\"tocnumber\">4.1</span> <span class=\"toctext\">United States</span></a></li>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#European_Union\"><span class=\"tocnumber\">4.2</span> <span class=\"toctext\">European Union</span></a></li>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#Other_countries\"><span class=\"tocnumber\">4.3</span> <span class=\"toctext\">Other countries</span></a></li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#Numbers_of_new_drugs\"><span class=\"tocnumber\">4.4</span> <span class=\"toctext\">Numbers of new drugs</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-9\"><a href=\"#Examples_for_selected_diseases\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Examples for selected diseases</span></a></li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#Activism,_research_centers\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Activism, research centers</span></a></li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#Cost\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">Cost</span></a></li>\n<li class=\"toclevel-1 tocsection-12\"><a href=\"#Public-funding\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">Public-funding</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-13\"><a href=\"#Evaluation_criteria\"><span class=\"tocnumber\">8.1</span> <span class=\"toctext\">Evaluation criteria</span></a></li>\n<li class=\"toclevel-2 tocsection-14\"><a href=\"#Abuse_potential\"><span class=\"tocnumber\">8.2</span> <span class=\"toctext\">Abuse potential</span></a></li>\n<li class=\"toclevel-2 tocsection-15\"><a href=\"#NICE\"><span class=\"tocnumber\">8.3</span> <span class=\"toctext\">NICE</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-16\"><a href=\"#See_also\"><span class=\"tocnumber\">9</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-17\"><a href=\"#References\"><span class=\"tocnumber\">10</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-18\"><a href=\"#External_links\"><span class=\"tocnumber\">11</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Definition\">Definition</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=1\" title=\"Edit section: Definition\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>An orphan drug is a <a href=\"/wiki/Medication\" title=\"Medication\">pharmaceutical agent</a> which has been developed to treat a rare medical condition, the condition itself being referred to as a <a href=\"/wiki/Rare_disease\" title=\"Rare disease\">rare disease</a>.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (July 2017)\">citation needed</span></a></i>&#93;</sup> A rare disease, also referred to as an \"orphan disease\", is any disease which affects a small percentage of the population. Most rare diseases are genetic, and thus are present throughout the person's entire life, even if symptoms do not immediately appear. Many rare diseases appear early in life, and about 30 percent of children with rare diseases will die before reaching their fifth birthday.<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup> No single cutoff number has been agreed upon for which a disease is considered rare.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (July 2017)\">citation needed</span></a></i>&#93;</sup> A disease may be considered rare in one part of the world, or in a particular group of people, but still be common in another.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (July 2017)\">citation needed</span></a></i>&#93;</sup> As many as one-in-ten Americans suffers from rare disease.<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Global_statistics\">Global statistics</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=2\" title=\"Edit section: Global statistics\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>As of  2014<sup class=\"plainlinks noexcerpt noprint asof-tag update\" style=\"display:none;\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Orphan_drug&amp;action=edit\">&#91;update&#93;</a></sup>, there were 281 marketed orphan drugs and more than 400 orphan designated drugs in clinical trials. More than 60% of orphan drugs were biologics. The US dominated the development of orphan drugs with more than 300 orphan drugs in clinical trial process, followed by Europe. <a href=\"/wiki/Cancer_treatment\" class=\"mw-redirect\" title=\"Cancer treatment\">Cancer treatment</a> was the indication in more than 30% for orphan drug clinical trials.<sup id=\"cite_ref-Kuick_2014_6-0\" class=\"reference\"><a href=\"#cite_note-Kuick_2014-6\">&#91;6&#93;</a></sup>\n</p>\n<ul><li>Number of orphan drugs in clinical trials: 600<sup id=\"cite_ref-Kuick_2014_6-1\" class=\"reference\"><a href=\"#cite_note-Kuick_2014-6\">&#91;6&#93;</a></sup></li>\n<li>Number of orphan drugs in Phase-2 Trial: 231<sup id=\"cite_ref-Kuick_2014_6-2\" class=\"reference\"><a href=\"#cite_note-Kuick_2014-6\">&#91;6&#93;</a></sup></li>\n<li>Number of orphan drugs in US clinical trials: 350 in the pipeline from research until registration<sup id=\"cite_ref-Kuick_2014_6-3\" class=\"reference\"><a href=\"#cite_note-Kuick_2014-6\">&#91;6&#93;</a></sup></li>\n<li>Key Market: US (Sales more than US$40 billion)<sup id=\"cite_ref-Kuick_2014_6-4\" class=\"reference\"><a href=\"#cite_note-Kuick_2014-6\">&#91;6&#93;</a></sup></li></ul>\n<h2><span id=\"Effect_on_investment.2C_sales_and_profit\"></span><span class=\"mw-headline\" id=\"Effect_on_investment,_sales_and_profit\">Effect on investment, sales and profit</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=3\" title=\"Edit section: Effect on investment, sales and profit\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>According to <a href=\"/wiki/Thomson_Reuters\" title=\"Thomson Reuters\">Thomson Reuters</a> in their 2012 publication \"The Economic Power of Orphan Drugs,\" there has been increased investing in orphan drug research and development partly due to the U. S. <a href=\"/wiki/Orphan_Drug_Act_of_1983\" title=\"Orphan Drug Act of 1983\">Orphan Drug Act of 1983</a> (ODA) and similar acts in other regions of the world and also driven by \"high-profile philanthropic funding.\"<sup id=\"cite_ref-ThomsonReuters_2012_7-0\" class=\"reference\"><a href=\"#cite_note-ThomsonReuters_2012-7\">&#91;7&#93;</a></sup><sup id=\"cite_ref-Economically_viable_2012_8-0\" class=\"reference\"><a href=\"#cite_note-Economically_viable_2012-8\">&#91;8&#93;</a></sup>\n</p><p>Per the trade journal <a href=\"/wiki/Drug_Discovery_Today\" title=\"Drug Discovery Today\">Drug Discovery Today</a> between 2001 and 2011 was the \"most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals.\"<sup id=\"cite_ref-Economically_viable_2012_8-1\" class=\"reference\"><a href=\"#cite_note-Economically_viable_2012-8\">&#91;8&#93;</a></sup><sup class=\"reference\" style=\"white-space:nowrap;\">:<span>660</span></sup> For the same decade the <a href=\"/wiki/Compound_annual_growth_rate\" title=\"Compound annual growth rate\">compound annual growth rate</a> (CAGR) of the orphan drugs was an \"impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs.\"<sup id=\"cite_ref-ThomsonReuters_2012_7-1\" class=\"reference\"><a href=\"#cite_note-ThomsonReuters_2012-7\">&#91;7&#93;</a></sup><sup class=\"reference\" style=\"white-space:nowrap;\">:<span>6</span></sup> \nBy 2012, the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs.<sup id=\"cite_ref-ThomsonReuters_2012_7-2\" class=\"reference\"><a href=\"#cite_note-ThomsonReuters_2012-7\">&#91;7&#93;</a></sup>\n</p><p>By 2012,\n</p>\n<style data-mw-deduplicate=\"TemplateStyles:r856303468\">.mw-parser-output .templatequote{overflow:hidden;margin:1em 0;padding:0 40px}.mw-parser-output .templatequote .templatequotecite{line-height:1.5em;text-align:left;padding-left:1.6em;margin-top:0}</style><blockquote class=\"templatequote\"><p>\"the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success.\"</p><div class=\"templatequotecite\">\u2014&#8201;<cite>Gaze and Breen 2012</cite></div>\n</blockquote>\n<p>According to a 2014 report, the orphan drug market has become increasingly lucrative for a number of reasons: The cost of clinical trials for orphan drugs is substantially lower than for other diseases \u2014trial sizes are naturally much smaller than for more common diseases with larger numbers of patients. Small clinical trials and little competition place orphan agents at an advantage in regulatory review.<sup id=\"cite_ref-EvaluatePharma_2014_2-1\" class=\"reference\"><a href=\"#cite_note-EvaluatePharma_2014-2\">&#91;2&#93;</a></sup>\n</p><p>Tax incentives reduce the cost of development. On average the cost per patient for orphan drugs is \"six times that of non-orphan drugs, a clear indication of their pricing power\". The cost of per-person outlays are huge and are expected to increase with wider use of public subsidies.<sup id=\"cite_ref-EvaluatePharma_2014_2-2\" class=\"reference\"><a href=\"#cite_note-EvaluatePharma_2014-2\">&#91;2&#93;</a></sup>\n</p><p>The 2014 Orphan Drug report stated that the percentage of orphan drug sales as part of all prescription drug sales had been increasing at rapid rate. By 2020 the total was predicted to be $176 billion.<sup id=\"cite_ref-EvaluatePharma_2014_2-3\" class=\"reference\"><a href=\"#cite_note-EvaluatePharma_2014-2\">&#91;2&#93;</a></sup> Although orphan disease populations are the smallest, the cost of per-patient outlays have been the largest. There pressure on pharmaceuticals which \"represent the biggest budgetary drain\" has been predicted to increase particularly as more people with rare diseases will be eligible for subsidies \u2014in the United States for example through the <a href=\"/wiki/Patient_Protection_and_Affordable_Care_Act\" title=\"Patient Protection and Affordable Care Act\">Affordable Care Act</a>.<sup id=\"cite_ref-EvaluatePharma_2014_2-4\" class=\"reference\"><a href=\"#cite_note-EvaluatePharma_2014-2\">&#91;2&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Legislation\">Legislation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=4\" title=\"Edit section: Legislation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Orphan drugs generally follow the same regulatory development path as any other pharmaceutical product, in which testing focuses on <a href=\"/wiki/Pharmacokinetics\" title=\"Pharmacokinetics\">pharmacokinetics</a> and <a href=\"/wiki/Pharmacodynamics\" title=\"Pharmacodynamics\">pharmacodynamics</a>, <a href=\"/wiki/Dosing\" title=\"Dosing\">dosing</a>, stability, safety and efficacy. However, some statistical burdens are lessened to maintain development momentum. For example, orphan drug regulations generally acknowledge the fact that it may not be possible to test 1,000 patients in a <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">phase III clinical trial</a>, as fewer than that number may be afflicted with the disease in question.\n</p><p>Since the market for any drug with such a limited application scope would, by definition, be small and thus largely unprofitable for pharmaceutical companies, some governments have chosen to intervene to motivate a manufacturer to develop an orphan drug.<sup id=\"cite_ref-EvaluatePharma_2014_2-5\" class=\"reference\"><a href=\"#cite_note-EvaluatePharma_2014-2\">&#91;2&#93;</a></sup>\n</p><p>The intervention by government on behalf of orphan drug development can take a variety of forms:\n</p>\n<ul><li><a href=\"/wiki/Tax_incentive\" title=\"Tax incentive\">Tax incentives</a></li>\n<li>Exclusivity (enhanced patent protection and marketing rights)</li>\n<li>Financial research subsidies</li>\n<li>Creating a government-run enterprise to engage in research and development as in a <a href=\"/wiki/Crown_corporation\" class=\"mw-redirect\" title=\"Crown corporation\">Crown corporation</a></li></ul>\n<p>A 2015 study of \"34 key Canadian stakeholders including drug regulators, funders, scientists, policy experts, pharmaceutical industry representatives, and patient advocates\"  investigated contributing factors to the growing interest of the pharmaceutical industry in \"niche markets\" such as orphan drugs.<sup id=\"cite_ref-World_Medicine_2015_9-0\" class=\"reference\"><a href=\"#cite_note-World_Medicine_2015-9\">&#91;9&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"United_States\">United States</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=5\" title=\"Edit section: United States\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The <a href=\"/wiki/Orphan_Drug_Act\" class=\"mw-redirect\" title=\"Orphan Drug Act\">Orphan Drug Act</a> (ODA) of January 1983, passed in the <a href=\"/wiki/United_States\" title=\"United States\">United States</a>, with lobbying from the <a href=\"/wiki/National_Organization_for_Rare_Disorders\" title=\"National Organization for Rare Disorders\">National Organization for Rare Disorders</a> and many other organizations,<sup id=\"cite_ref-henkel_10-0\" class=\"reference\"><a href=\"#cite_note-henkel-10\">&#91;10&#93;</a></sup> is meant to encourage <a href=\"/wiki/Pharmaceutical_company\" class=\"mw-redirect\" title=\"Pharmaceutical company\">pharmaceutical companies</a> to develop drugs for diseases that have a small market.<sup id=\"cite_ref-nyt_11-0\" class=\"reference\"><a href=\"#cite_note-nyt-11\">&#91;11&#93;</a></sup> Under the ODA drugs, vaccines, and diagnostic agents would qualify for orphan status if they were intended to treat a disease affecting less than 200,000 American citizens. Under the ODA orphan drug sponsors qualify for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), \"tax credits of up to 50% of R&amp;D costs, R&amp;D grants, waived FDA fees, protocol assistance<sup id=\"cite_ref-Economically_viable_2012_8-2\" class=\"reference\"><a href=\"#cite_note-Economically_viable_2012-8\">&#91;8&#93;</a></sup><sup class=\"reference\" style=\"white-space:nowrap;\">:<span>660</span></sup> and may get clinical trial <a href=\"/wiki/Tax_incentive\" title=\"Tax incentive\">tax incentives</a>.<sup id=\"cite_ref-nyt_11-1\" class=\"reference\"><a href=\"#cite_note-nyt-11\">&#91;11&#93;</a></sup>\n</p><p>Orphan drug designation means that the sponsor qualifies for certain benefits but it does not mean the drug is safe and effective and legal to manufacture and market in the United States.\n</p><p>In 2002, the <a href=\"/wiki/Rare_Diseases_Act_of_2002\" title=\"Rare Diseases Act of 2002\">Rare Diseases Act</a> was signed into law. It amended the <a href=\"/wiki/Public_Health_Service_Act\" title=\"Public Health Service Act\">Public Health Service Act</a> to establish the <a href=\"/wiki/Office_of_Rare_Diseases\" class=\"mw-redirect\" title=\"Office of Rare Diseases\">Office of Rare Diseases</a>. It also increased funding for the development of treatments for people with <a href=\"/wiki/Rare_diseases\" class=\"mw-redirect\" title=\"Rare diseases\">rare diseases</a>.<sup id=\"cite_ref-Law_12-0\" class=\"reference\"><a href=\"#cite_note-Law-12\">&#91;12&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"European_Union\">European Union</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=6\" title=\"Edit section: European Union\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In 2000, the <a href=\"/wiki/European_Union\" title=\"European Union\">European Union</a> (EU) has enacted similar legislation, Regulation(EC) No 141/2000, which refers to drugs developed to treat rare diseases to as \"orphan medicinal products\". The EU's definition of an orphan condition is broader than that of the USA, in that it also covers some tropical diseases that are primarily found in developing nations.<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup> Orphan drug status granted by the European Commission gives marketing exclusivity in the EU for 10 years after approval.<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup> The EU's legislation is administered by the <a href=\"/wiki/Committee_on_Orphan_Medicinal_Products\" class=\"mw-redirect\" title=\"Committee on Orphan Medicinal Products\">Committee on Orphan Medicinal Products</a> of the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a> (EMA).\n</p><p>In late 2007 the FDA and EMA agreed to use a common application process for both agencies to make it easier for manufacturers to apply for orphan drug status but, while continuing two separate approval processes.<sup id=\"cite_ref-BWN112007_15-0\" class=\"reference\"><a href=\"#cite_note-BWN112007-15\">&#91;15&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Other_countries\">Other countries</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=7\" title=\"Edit section: Other countries\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Legislation has been implemented by Japan, Singapore, and Australia that offers subsidies and other incentives to encourage the development of drugs that treat orphan diseases.<sup id=\"cite_ref-Windsor_16-0\" class=\"reference\"><a href=\"#cite_note-Windsor-16\">&#91;16&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Numbers_of_new_drugs\">Numbers of new drugs</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=8\" title=\"Edit section: Numbers of new drugs\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Under the ODA and EU legislation, many orphan drugs have been developed, including drugs to treat <a href=\"/wiki/Glioma\" title=\"Glioma\">glioma</a>, <a href=\"/wiki/Multiple_myeloma\" title=\"Multiple myeloma\">multiple myeloma</a>, <a href=\"/wiki/Cystic_fibrosis\" title=\"Cystic fibrosis\">cystic fibrosis</a>, <a href=\"/wiki/Phenylketonuria\" title=\"Phenylketonuria\">phenylketonuria</a>, <a href=\"/wiki/Snake_venom\" title=\"Snake venom\">snake venom</a> poisoning, and <a href=\"/wiki/Idiopathic_thrombocytopenic_purpura\" class=\"mw-redirect\" title=\"Idiopathic thrombocytopenic purpura\">idiopathic thrombocytopenic purpura</a>.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (July 2017)\">citation needed</span></a></i>&#93;</sup>\n</p><p>The Pharmaceitical Executive opines, that the \"ODA is nearly universally acknowledged to be a success\".<sup id=\"cite_ref-Executive_1-1\" class=\"reference\"><a href=\"#cite_note-Executive-1\">&#91;1&#93;</a></sup>\n</p><p>Before the <a href=\"/wiki/United_States_Congress\" title=\"United States Congress\">United States Congress</a> enacted the ODA in 1983, only 38 drugs were approved in the USA specifically to treat orphan diseases.<sup id=\"cite_ref-Daly_2002_3-1\" class=\"reference\"><a href=\"#cite_note-Daly_2002-3\">&#91;3&#93;</a></sup> \nIn the USA, from January 1983 to June 2004, the Office of Orphan Products Development 249 orphan drugs received marketing authorization and granted 1,129 different orphan drug designations, compared to fewer than ten such products in the decade prior to 1983. \nFrom 1983 until May 2010, the FDA approved 353 orphan drugs and granted orphan designations to 2,116 compounds. \nAs of 2010, 200 of the roughly 7,000 officially designated orphan diseases have become treatable.<sup id=\"cite_ref-Executive_1-2\" class=\"reference\"><a href=\"#cite_note-Executive-1\">&#91;1&#93;</a></sup>\n</p><p>Critics have questioned whether orphan drug legislation was the real cause of this increase, claiming that many of the new drugs were for disorders which were already being researched anyway, and would have had drugs developed regardless of the legislation, and whether the ODA has truly  stimulated the production of non-profitable drugs; the act also has been criticised for allowing some pharmaceutical companies to make a large profit of drugs which have a small market but sell for a high price.<sup id=\"cite_ref-nyt_11-2\" class=\"reference\"><a href=\"#cite_note-nyt-11\">&#91;11&#93;</a></sup>\n</p><p>While the European Medicines Agency grants orphan drugs market access to all member states, in practice, they only reach the market when a member state decides that its national health system will reimburse for the drug. For example, in 2008, 44 orphan drugs reached the market in the Netherlands, 35 in Belgium, and 28 in Sweden, while in 2007, 35 such drugs reached the market in France and 23 in Italy.<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup>\n</p><p>Though not technically an orphan disease, the research and development into the treatment for <a href=\"/wiki/AIDS\" class=\"mw-redirect\" title=\"AIDS\">AIDS</a> has been heavily linked to the <a href=\"/wiki/Orphan_Drug_Act\" class=\"mw-redirect\" title=\"Orphan Drug Act\">Orphan Drug Act</a>. In the beginning of the AIDS epidemic the lack of treatment for the disease was often accredited to a believed lack of commercial base for a medication linked to <a href=\"/wiki/HIV\" title=\"HIV\">HIV</a> infection. This encouraged the FDA to use the Orphan Drug Act to help bolster research in this field, and by 1995 13 of the 19 drugs approved by the FDA to treat AIDS had received orphan drug designation, with 10 receiving marketing rights. These are in addition to the 70 designated orphan drugs designed to treat other HIV related illnesses.<sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Examples_for_selected_diseases\">Examples for selected diseases</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=9\" title=\"Edit section: Examples for selected diseases\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In the 1980s, people with <a href=\"/wiki/Cystic_fibrosis\" title=\"Cystic fibrosis\">cystic fibrosis</a> rarely lived beyond their early teens. Drugs like <a href=\"/wiki/Pulmozyme\" class=\"mw-redirect\" title=\"Pulmozyme\">Pulmozyme</a> and <a href=\"/wiki/Tobramycin\" title=\"Tobramycin\">tobramycin</a>, both developed with aid from the ODA, revolutionized treatment for cystic fibrosis patients by significantly improving their quality of life and extending their life expectancies. Now, cystic fibrosis patients often survive into their thirties and some into their fifties.<sup id=\"cite_ref-Law_12-1\" class=\"reference\"><a href=\"#cite_note-Law-12\">&#91;12&#93;</a></sup>\n</p><p>The 1985 Nobel Prize for medicine went to two researchers for their work related to  <a href=\"/wiki/Familial_hypercholesterolemia\" title=\"Familial hypercholesterolemia\">familial hypercholesterolemia</a>, which causes large and rapid increases in cholesterol levels. Their research led to the development of <a href=\"/wiki/Statins\" class=\"mw-redirect\" title=\"Statins\">statin drugs</a> which are now commonly used to treat high cholesterol.<sup id=\"cite_ref-Windsor_16-1\" class=\"reference\"><a href=\"#cite_note-Windsor-16\">&#91;16&#93;</a></sup>\n</p><p><a href=\"/wiki/Penicillamine\" title=\"Penicillamine\">Penicillamine</a> was developed to treat <a href=\"/wiki/Wilson%27s_disease\" title=\"Wilson&#39;s disease\">Wilson's disease</a>, a rare hereditary disease that can lead to a fatal accumulation of copper in the body. This drug was later found to be effective in treating <a href=\"/wiki/Arthritis\" title=\"Arthritis\">arthritis</a>.<sup id=\"cite_ref-Windsor_16-2\" class=\"reference\"><a href=\"#cite_note-Windsor-16\">&#91;16&#93;</a></sup> <a href=\"/wiki/Bis-choline_tetrathiomolybdate\" title=\"Bis-choline tetrathiomolybdate\">Bis-choline tetrathiomolybdate</a> is currently under investigation as a therapy against Wilson's disease.\n</p>\n<h2><span id=\"Activism.2C_research_centers\"></span><span class=\"mw-headline\" id=\"Activism,_research_centers\">Activism, research centers</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=10\" title=\"Edit section: Activism, research centers\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The <a href=\"/w/index.php?title=Center_for_Orphan_Drug_Research&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Center for Orphan Drug Research (page does not exist)\">Center for Orphan Drug Research</a> at the <a href=\"/wiki/University_of_Minnesota\" title=\"University of Minnesota\">University of Minnesota</a> College of Pharmacy helps small companies with insufficient in-house expertise and resources in drug synthesis, formulation, pharmacometrics, and bio-analysis.<sup id=\"cite_ref-Technology_19-0\" class=\"reference\"><a href=\"#cite_note-Technology-19\">&#91;19&#93;</a></sup>\nThe <a href=\"/wiki/Keck_Graduate_Institute\" title=\"Keck Graduate Institute\">Keck Graduate Institute</a> Center for Rare Disease Therapies (CRDT) in Claremont, California, supports projects to revive potential orphan drugs whose development has stalled by identifying barriers to commercialization, such as problems with formulation and bio-processing.<sup id=\"cite_ref-Technology_19-1\" class=\"reference\"><a href=\"#cite_note-Technology-19\">&#91;19&#93;</a></sup>\n</p><p>Numerous advocacy groups such as the <a href=\"/wiki/National_Organization_for_Rare_Disorders\" title=\"National Organization for Rare Disorders\">National Organization for Rare Disorders</a>, <a href=\"/wiki/Global_Genes_Project\" class=\"mw-redirect\" title=\"Global Genes Project\">Global Genes Project</a>, Children's Rare Disease Network, Abetalipoproteinemia Collaboration Foundation, Zellweger Baby Support Network, and the Friedreich's Ataxia Research Alliance have been founded in order to advocate on behalf of  patients suffering from rare diseases with a particular emphasis on diseases that afflict children.<sup id=\"cite_ref-Executive_1-3\" class=\"reference\"><a href=\"#cite_note-Executive-1\">&#91;1&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Cost\">Cost</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=11\" title=\"Edit section: Cost\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>According to a 2015 report published by EvaluatePharma, the economics of orphan drugs mirrors the economics of the pharmaceutical market as a whole but has a few very large differences.<sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup> The market for orphan drugs is by definition very small, but while the customer base is drastically smaller the cost of research and development is very much the same as for non orphan drugs. This, the producers have claimed, causes them to charge extremely high amounts for treatment sometimes as high as $700,000 a year, as in the case of <a href=\"/wiki/Spinraza\" class=\"mw-redirect\" title=\"Spinraza\">Spinraza</a> (Biogen), FDA approved in December 2016 for spinal muscular atrophy,<sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup> placing a large amount of stress on insurance companies and patients. An analysis of 12 orphan drugs that were approved in the US between 1990 and 2000 estimated a price reduction of on average 50% upon loss of marketing exclusivity, with a range of price reductions from 14% to 95%.<sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup>\n</p><p>Governments have implemented steps to reduce high research and development cost with subsidies and other forms of financial assistance. The largest assistance are tax breaks which can be as high as 50% of research and development costs.<sup id=\"cite_ref-meek_23-0\" class=\"reference\"><a href=\"#cite_note-meek-23\">&#91;23&#93;</a></sup> Orphan drug manufacturers are also able to take advantage of the small customer base to cut cost on clinical trials due to the small number of cases to have smaller trials which reduces cost. These smaller clinical trials also allow orphan drugs to move to market faster as the average time to receive FDA approval for an orphan drug is 10 months compared to 13 months for non-orphan drugs. This is especially true in the market for cancer drugs, as a 2011 study found that between 2004 and 2010 orphan drug trials were more likely to be smaller and less randomized than their non-orphan counterparts, but still had a higher FDA approval rate, with 15 orphan cancer drugs being approved, while only 12 non-orphan drugs were approved.<sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup> This allows manufactures to get cost to the point that it is economically feasible to produce these treatments.<sup id=\"cite_ref-meek_23-1\" class=\"reference\"><a href=\"#cite_note-meek-23\">&#91;23&#93;</a></sup> The subsidies can total up to 30 million dollars per fiscal year in the United States alone<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"Your explanation here (April 2017)\">citation needed</span></a></i>&#93;</sup>.\n</p><p>\nBy 2015, industry analysts and academic researchers agreed, that the sky-high price of orphan drugs, such as <a href=\"/wiki/Eculizumab\" title=\"Eculizumab\">eculizumab</a>, was not related to research, development and manufacturing costs. Their price is arbitrary and they have become more profitable than traditional medicines.<sup id=\"cite_ref-CBC_Crowe_2015_25-0\" class=\"reference\"><a href=\"#cite_note-CBC_Crowe_2015-25\">&#91;25&#93;</a></sup></p><link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r856303468\"/><blockquote class=\"templatequote\"><p>\"Public resources went into understanding the molecular basis of the disease, public resources went into the technology to make antibodies and finally, Alexion, to their credit, kind of picked up the pieces.\"</p><div class=\"templatequotecite\">\u2014&#8201;<cite>Sachdev Sidhu 2015</cite></div>\n</blockquote>\n<h2><span class=\"mw-headline\" id=\"Public-funding\">Public-funding</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=12\" title=\"Edit section: Public-funding\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Evaluation_criteria\">Evaluation criteria</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=13\" title=\"Edit section: Evaluation criteria\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>By 2007 the use of economic evaluation methods regarding public-funding of orphan drugs, using estimates of the incremental cost-effectiveness, for example, became more established internationally.<sup id=\"cite_ref-Drummond_2007_26-0\" class=\"reference\"><a href=\"#cite_note-Drummond_2007-26\">&#91;26&#93;</a></sup> The QALY has often been used in <a href=\"/wiki/Cost-utility_analysis\" class=\"mw-redirect\" title=\"Cost-utility analysis\">cost-utility analysis</a> to calculate the ratio of cost to QALYs saved for a particular health care intervention.<sup id=\"cite_ref-NICE_2010_27-0\" class=\"reference\"><a href=\"#cite_note-NICE_2010-27\">&#91;27&#93;</a></sup><sup id=\"cite_ref-28\" class=\"reference\"><a href=\"#cite_note-28\">&#91;28&#93;</a></sup> By 2008 the National Institute for Health and Care Excellence (NICE) in England and Wales, for example, operated with a threshold range of \u00a320,000\u2013\u00a330,000 per <a href=\"/wiki/Quality-adjusted_life_year\" title=\"Quality-adjusted life year\">Quality-adjusted life year</a> (QALY).<sup id=\"cite_ref-Eurohealth_2008_29-0\" class=\"reference\"><a href=\"#cite_note-Eurohealth_2008-29\">&#91;29&#93;</a></sup>  By 2005 doubts were raised about the use of economic evaluations in orphan drugs.<sup id=\"cite_ref-Drummond_2007_26-1\" class=\"reference\"><a href=\"#cite_note-Drummond_2007-26\">&#91;26&#93;</a></sup> By 2008 most of the orphan drugs appraised had cost-effectiveness thresholds \"well in excess of the \u2018accepted\u2019 level and would not be reimbursed according to conventional criteria.\"<sup id=\"cite_ref-Eurohealth_2008_29-1\" class=\"reference\"><a href=\"#cite_note-Eurohealth_2008-29\">&#91;29&#93;</a></sup> As early as 2005 McCabe et al argued<sup id=\"cite_ref-McCabe_2005_30-0\" class=\"reference\"><a href=\"#cite_note-McCabe_2005-30\">&#91;30&#93;</a></sup><sup id=\"cite_ref-McCabe_2007_31-0\" class=\"reference\"><a href=\"#cite_note-McCabe_2007-31\">&#91;31&#93;</a></sup> that rarity should not have a premium and orphan drugs should be treated like other pharmaceuticals in general.<sup id=\"cite_ref-McCabe_2005_30-1\" class=\"reference\"><a href=\"#cite_note-McCabe_2005-30\">&#91;30&#93;</a></sup><sup id=\"cite_ref-McCabe_2007_31-1\" class=\"reference\"><a href=\"#cite_note-McCabe_2007-31\">&#91;31&#93;</a></sup> Drummond et al<sup id=\"cite_ref-McCabe_2007_31-2\" class=\"reference\"><a href=\"#cite_note-McCabe_2007-31\">&#91;31&#93;</a></sup> argued that the social value of health technologies should also be included in the assessment along than the estimation of the incremental cost-effectiveness ratio.\n</p>\n<h3><span class=\"mw-headline\" id=\"Abuse_potential\">Abuse potential</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=14\" title=\"Edit section: Abuse potential\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:222px;\"><a href=\"/wiki/File:Rosuvastatin-Formulae_V_1.png\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/bb/Rosuvastatin-Formulae_V_1.png/220px-Rosuvastatin-Formulae_V_1.png\" width=\"220\" height=\"108\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/bb/Rosuvastatin-Formulae_V_1.png/330px-Rosuvastatin-Formulae_V_1.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/bb/Rosuvastatin-Formulae_V_1.png/440px-Rosuvastatin-Formulae_V_1.png 2x\" data-file-width=\"3194\" data-file-height=\"1567\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Rosuvastatin-Formulae_V_1.png\" class=\"internal\" title=\"Enlarge\"></a></div>Rosuvastatin (brand name Crestor) is an example of a drug that received Orphan Drug funding but was later marketed to a large consumer base.</div></div></div>\n<p>The very large incentives given to pharmaceutical companies to produce orphan drugs have led to the impression that the financial support afforded to make these drugs possible is akin to abuse.<sup id=\"cite_ref-32\" class=\"reference\"><a href=\"#cite_note-32\">&#91;32&#93;</a></sup> Because drugs can be used to treat multiple conditions, companies can take drugs that were filed with their government agency as orphan drugs to receive financial assistance, and then market it to a wide population to increase their <a href=\"/wiki/Profit_margin\" title=\"Profit margin\">profit margin</a>. For example <a href=\"/wiki/AstraZeneca\" title=\"AstraZeneca\">AstraZeneca</a>'s cholesterol drug <a href=\"/wiki/Rosuvastatin\" title=\"Rosuvastatin\">Crestor</a> was filed as a treatment for the rare disease pediatric <a href=\"/wiki/Familial_hypercholesterolemia\" title=\"Familial hypercholesterolemia\">familial hypercholesterolemia</a>. After the drug was approved for orphan drug designation, and AstraZeneca had received tax breaks and other advantages, AstraZeneca later applied and received FDA approval for the drug to be used to treat cholesterol in all diabetics.<sup id=\"cite_ref-Windsor_16-3\" class=\"reference\"><a href=\"#cite_note-Windsor-16\">&#91;16&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"NICE\">NICE</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=15\" title=\"Edit section: NICE\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>By 2008 if an orphan drug cost more than \u00a330,000<sup class=\"noprint Inline-Template\" style=\"margin-left:0.1em; white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Please_clarify\" title=\"Wikipedia:Please clarify\"><span title=\"30k per patient? For total cost of treatment? Per some time period? (July 2015)\">clarification needed</span></a></i>&#93;</sup> the <a href=\"/wiki/National_Institute_for_Health_and_Care_Excellence\" title=\"National Institute for Health and Care Excellence\">NICE</a> required other arguments for funding.<sup id=\"cite_ref-Eurohealth_2008_29-2\" class=\"reference\"><a href=\"#cite_note-Eurohealth_2008-29\">&#91;29&#93;</a></sup>\n</p><p>In 2015, NICE held consultations with \"patient groups, the Department of Health, companies, learned societies, charities and researchers\" regarding the appraisal of medicines and other technologies. There was a call for more research into new processes including the <sup id=\"cite_ref-NICE_2014_33-0\" class=\"reference\"><a href=\"#cite_note-NICE_2014-33\">&#91;33&#93;</a></sup>\n</p>\n<link rel=\"mw-deduplicated-inline-style\" href=\"mw-data:TemplateStyles:r856303468\"/><blockquote class=\"templatequote\"><p>\"model of pharmaceutical research and development, the expectations that companies and patient groups have about how risk and reward is shared between the industry and a publicly funded NHS, and in the arrangements for commissioning expensive new treatments.\"</p><div class=\"templatequotecite\">\u2014&#8201;<cite>NICE 2014</cite></div>\n</blockquote>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=16\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Drug_development\" title=\"Drug development\">Drug development</a></li>\n<li><a href=\"/wiki/European_Organization_for_Rare_Diseases\" class=\"mw-redirect\" title=\"European Organization for Rare Diseases\">European Organization for Rare Diseases</a></li>\n<li><a href=\"/wiki/Supplementary_protection_certificate\" title=\"Supplementary protection certificate\">Supplementary protection certificate</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=17\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-Executive-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Executive_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Executive_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Executive_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Executive_1-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Armstrong, Walter (May 2010). \"Pharma's Orphans\". <i>Pharmaceutical Executive</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmaceutical+Executive&amp;rft.atitle=Pharma%27s+Orphans&amp;rft.date=2010-05&amp;rft.au=Armstrong%2C+Walter&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-EvaluatePharma_2014-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-EvaluatePharma_2014_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-EvaluatePharma_2014_2-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-EvaluatePharma_2014_2-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-EvaluatePharma_2014_2-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-EvaluatePharma_2014_2-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-EvaluatePharma_2014_2-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><cite id=\"CITEREFHadjivasiliou2014\" class=\"citation\">Hadjivasiliou, Andreas (October 2014), <a rel=\"nofollow\" class=\"external text\" href=\"http://info.evaluategroup.com/rs/evaluatepharmaltd/images/2014OD.pdf\">\"Orphan Drug Report 2014\"</a> <span style=\"font-size:85%;\">(PDF)</span>, <i>EvaluatePharma</i><span class=\"reference-accessdate\">, retrieved <span class=\"nowrap\">28 June</span> 2015</span></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=EvaluatePharma&amp;rft.atitle=Orphan+Drug+Report+2014&amp;rft.date=2014-10&amp;rft.aulast=Hadjivasiliou&amp;rft.aufirst=Andreas&amp;rft_id=http%3A%2F%2Finfo.evaluategroup.com%2Frs%2Fevaluatepharmaltd%2Fimages%2F2014OD.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Daly_2002-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Daly_2002_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Daly_2002_3-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Rich Daly (5 September 2002). \"House Offers Incentives For Development of 'Orphan' Drugs\". <i>Congressional Quarterly Daily Monitor</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Congressional+Quarterly+Daily+Monitor&amp;rft.atitle=House+Offers+Incentives+For+Development+of+%27Orphan%27+Drugs&amp;rft.date=2002-09-05&amp;rft.au=Rich+Daly&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20121203212325/http://www.siope.eu/SIOPE-EU/English/SIOPE-EU/Advocacy-Activities/Rare-Diseases/page.aspx/148\">\"Archived copy\"</a>. Archived from the original on December 3, 2012<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-09-24</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Archived+copy&amp;rft_id=http%3A%2F%2Fwww.siope.eu%2FSIOPE-EU%2FEnglish%2FSIOPE-EU%2FAdvocacy-Activities%2FRare-Diseases%2Fpage.aspx%2F148&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: BOT: original-url status unknown (<a href=\"/wiki/Category:CS1_maint:_BOT:_original-url_status_unknown\" title=\"Category:CS1 maint: BOT: original-url status unknown\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Andrew Duffy (25 January 2002). \"Rare diseases' troubling questions\". <i>Cobourg Daily Star (Ontario)</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cobourg+Daily+Star+%28Ontario%29&amp;rft.atitle=Rare+diseases%27+troubling+questions&amp;rft.date=2002-01-25&amp;rft.au=Andrew+Duffy&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Kuick_2014-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Kuick_2014_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Kuick_2014_6-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Kuick_2014_6-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Kuick_2014_6-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Kuick_2014_6-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.prnewswire.com/news-releases/global-orphan-drug-market-to-reach-us-120-billion-by-2018-244195511.html\"><i>Global orphan drug market to reach US$ 120 billion by 2018</i></a> <span style=\"font-size:85%;\">(press release)</span>, New Delhi: Kuick Research, 7 Feb 2014<span class=\"reference-accessdate\">, retrieved <span class=\"nowrap\">20 March</span> 2014</span></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Global+orphan+drug+market+to+reach+US%24+120+billion+by+2018&amp;rft.place=New+Delhi&amp;rft.pub=Kuick+Research&amp;rft.date=2014-02-07&amp;rft_id=http%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fglobal-orphan-drug-market-to-reach-us-120-billion-by-2018-244195511.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ThomsonReuters_2012-7\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ThomsonReuters_2012_7-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ThomsonReuters_2012_7-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-ThomsonReuters_2012_7-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation\">Laura Gaze, Jennifer Breen (2012), <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20150513083426/http://thomsonreuters.com/content/dam/openweb/documents/pdf/pharma-life-sciences/white-paper/1001450.pdf\">\"The Economic Power of Orphan Drugs\"</a> <span style=\"font-size:85%;\">(PDF)</span>, <i>Thomson Reuters</i>, archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://thomsonreuters.com/content/dam/openweb/documents/pdf/pharma-life-sciences/white-paper/1001450.pdf\">the original</a> <span style=\"font-size:85%;\">(PDF)</span> on 13 May 2015<span class=\"reference-accessdate\">, retrieved <span class=\"nowrap\">29 June</span> 2015</span></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Thomson+Reuters&amp;rft.atitle=The+Economic+Power+of+Orphan+Drugs&amp;rft.date=2012&amp;rft_id=http%3A%2F%2Fthomsonreuters.com%2Fcontent%2Fdam%2Fopenweb%2Fdocuments%2Fpdf%2Fpharma-life-sciences%2Fwhite-paper%2F1001450.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Uses authors parameter (<a href=\"/wiki/Category:CS1_maint:_Uses_authors_parameter\" title=\"Category:CS1 maint: Uses authors parameter\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-Economically_viable_2012-8\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Economically_viable_2012_8-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Economically_viable_2012_8-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Economically_viable_2012_8-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation\">Kiran N. Meeking, Cory S.M. Williams, John E. Arrowsmith (15 August 2012), <a rel=\"nofollow\" class=\"external text\" href=\"http://www.drugdiscoverytoday.com/download/900\">\"Orphan drug development: an economically viable strategy for biopharma R&amp;D\"</a>, <i>Drug Discovery Today</i>, <b>17</b>: 660\u2013664, <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.drudis.2012.02.005\">10.1016/j.drudis.2012.02.005</a>, <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/22366309\">22366309</a><span class=\"reference-accessdate\">, retrieved <span class=\"nowrap\">29 June</span> 2015</span></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drug+Discovery+Today&amp;rft.atitle=Orphan+drug+development%3A+an+economically+viable+strategy+for+biopharma+R%26D&amp;rft.volume=17&amp;rft.pages=660-664&amp;rft.date=2012-08-15&amp;rft_id=info%3Adoi%2F10.1016%2Fj.drudis.2012.02.005&amp;rft_id=info%3Apmid%2F22366309&amp;rft_id=http%3A%2F%2Fwww.drugdiscoverytoday.com%2Fdownload%2F900&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Uses authors parameter (<a href=\"/wiki/Category:CS1_maint:_Uses_authors_parameter\" title=\"Category:CS1 maint: Uses authors parameter\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-World_Medicine_2015-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-World_Medicine_2015_9-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Shannon Gibson, Hamid R Raziee, and Trudo Lemmens (19 March 2015). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4405057\">\"Why the Shift? Taking a Closer Look at the Growing Interest in Niche Markets and Personalized Medicine\"</a>. <i>World Medicine Health Policy</i>. <b>7</b> (1): 3\u201327. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/wmh3.131\">10.1002/wmh3.131</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4405057\">4405057</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25914853\">25914853</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=World+Medicine+Health+Policy&amp;rft.atitle=Why+the+Shift%3F+Taking+a+Closer+Look+at+the+Growing+Interest+in+Niche+Markets+and+Personalized+Medicine&amp;rft.volume=7&amp;rft.issue=1&amp;rft.pages=3-27&amp;rft.date=2015-03-19&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4405057&amp;rft_id=info%3Apmid%2F25914853&amp;rft_id=info%3Adoi%2F10.1002%2Fwmh3.131&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4405057&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Uses authors parameter (<a href=\"/wiki/Category:CS1_maint:_Uses_authors_parameter\" title=\"Category:CS1 maint: Uses authors parameter\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-henkel-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-henkel_10-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Henkel, John (1999). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/Fdac/features/1999/399_orph.html\">\"Orphan Drug Law Matures into Medical Mainstay\"</a>. <i><a href=\"/wiki/FDA_Consumer\" title=\"FDA Consumer\">FDA Consumer</a></i>. <a href=\"/wiki/U.S._Food_and_Drug_Administration\" class=\"mw-redirect\" title=\"U.S. Food and Drug Administration\">U.S. Food and Drug Administration</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">14 February</span> 2009</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=FDA+Consumer&amp;rft.atitle=Orphan+Drug+Law+Matures+into+Medical+Mainstay&amp;rft.date=1999&amp;rft.aulast=Henkel&amp;rft.aufirst=John&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FFdac%2Ffeatures%2F1999%2F399_orph.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-nyt-11\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-nyt_11-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-nyt_11-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-nyt_11-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">Pollack, Andrew (30 April 1990). <a rel=\"nofollow\" class=\"external text\" href=\"https://query.nytimes.com/gst/fullpage.html?sec=health&amp;res=9C0CE4DF1F3EF933A05757C0A966958260\">\"Orphan Drug Law Spurs Debate\"</a>. <i><a href=\"/wiki/The_New_York_Times\" title=\"The New York Times\">The New York Times</a></i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">15 February</span> 2009</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Orphan+Drug+Law+Spurs+Debate&amp;rft.date=1990-04-30&amp;rft.aulast=Pollack&amp;rft.aufirst=Andrew&amp;rft_id=https%3A%2F%2Fquery.nytimes.com%2Fgst%2Ffullpage.html%3Fsec%3Dhealth%26res%3D9C0CE4DF1F3EF933A05757C0A966958260&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Law-12\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Law_12-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Law_12-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Illingworth, Patricia; Cohen, Jillian; Illingworth, P (2004). \"Orphan Drug Policies: Implications for the United States, Canada, and Developing Countries\". <i>Health Law Journal</i>. <b>12</b>: 183\u2013200. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/16539081\">16539081</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Law+Journal&amp;rft.atitle=Orphan+Drug+Policies%3A+Implications+for+the+United+States%2C+Canada%2C+and+Developing+Countries&amp;rft.volume=12&amp;rft.pages=183-200&amp;rft.date=2004&amp;rft_id=info%3Apmid%2F16539081&amp;rft.aulast=Illingworth&amp;rft.aufirst=Patricia&amp;rft.au=Cohen%2C+Jillian&amp;rft.au=Illingworth%2C+P&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.medterms.com/script/main/art.asp?articlekey=11418\">\"Orphan disease definition - Medical Dictionary definitions of popular medical terms easily defined on MedTerms\"</a>. Medterms.com. 2002-08-25<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2010-06-07</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Orphan+disease+definition+-+Medical+Dictionary+definitions+of+popular+medical+terms+easily+defined+on+MedTerms&amp;rft.pub=Medterms.com&amp;rft.date=2002-08-25&amp;rft_id=http%3A%2F%2Fwww.medterms.com%2Fscript%2Fmain%2Fart.asp%3Farticlekey%3D11418&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Gerke, Sara; Pattinson, Shaun D. (2017-02-09). <a rel=\"nofollow\" class=\"external text\" href=\"http://booksandjournals.brillonline.com/content/journals/10.1163/15718093-12341439\">\"EU Marketing Authorisation of Orphan Medicinal Products and Its Impact on Related Research\"</a>. <i>Brill</i>. <b>24</b>: 541\u2013564. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1163/15718093-12341439\">10.1163/15718093-12341439</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Brill&amp;rft.atitle=EU+Marketing+Authorisation+of+Orphan+Medicinal+Products+and+Its+Impact+on+Related+Research&amp;rft.volume=24&amp;rft.pages=541-564&amp;rft.date=2017-02-09&amp;rft_id=info%3Adoi%2F10.1163%2F15718093-12341439&amp;rft.aulast=Gerke&amp;rft.aufirst=Sara&amp;rft.au=Pattinson%2C+Shaun+D.&amp;rft_id=http%3A%2F%2Fbooksandjournals.brillonline.com%2Fcontent%2Fjournals%2F10.1163%2F15718093-12341439&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-BWN112007-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-BWN112007_15-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Donna Young (2007-11-28). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.pharmasentry.com/news/newsletter.cfm?linkid=CE077395-1372-54C2-61CFB42D06A278FB\">\"U.S., EU Will Use Same Orphan Drug Application.\"</a> <i>BioWorld News</i>. Washington. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?forceid=46273&amp;next=bioWorldToday_article&amp;search=1&amp;prodID=4&amp;htsid=0&amp;htmax=237\">the original</a> on 2007-12-11<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2008-01-06</span></span>. <q>In an attempt to simplify the process for obtaining orphan status for medications targeting rare diseases, the FDA and the European Medicines Agency (EMA) have created a common application. ... U.S. and European regulators still will conduct independent reviews of application submissions to ensure the data submitted meet the legal and scientific requirements of their respective jurisdictions, the agencies said.</q></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BioWorld+News&amp;rft.atitle=U.S.%2C+EU+Will+Use+Same+Orphan+Drug+Application.&amp;rft.date=2007-11-28&amp;rft.au=Donna+Young&amp;rft_id=http%3A%2F%2Fwww.bioworld.com%2Fservlet%2Fcom.accumedia.web.Dispatcher%3Fforceid%3D46273%26next%3DbioWorldToday_article%26search%3D1%26prodID%3D4%26htsid%3D0%26htmax%3D237&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Windsor-16\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Windsor_16-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Windsor_16-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Windsor_16-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Windsor_16-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Andrew Duffy (23 February 2002). \"ORPHAN DISEASES A RARE OCCURRENCE: A desperate search for help; County family joins long list with rare diseases in seeking a miracle\". <i>Windsor Star (Ontario)</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Windsor+Star+%28Ontario%29&amp;rft.atitle=ORPHAN+DISEASES+A+RARE+OCCURRENCE%3A+A+desperate+search+for+help%3B+County+family+joins+long+list+with+rare+diseases+in+seeking+a+miracle&amp;rft.date=2002-02-23&amp;rft.au=Andrew+Duffy&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Denis, Alain; Mergaert, Lut; Fostier, Christel;  et al. (2010). \"Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe\". <i>Applied Health Economics and Health Policy</i>. <b>8</b> (5): 341. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.2165/11536990-000000000-00000\">10.2165/11536990-000000000-00000</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Applied+Health+Economics+and+Health+Policy&amp;rft.atitle=Issues+Surrounding+Orphan+Disease+and+Orphan+Drug+Policies+in+Europe&amp;rft.volume=8&amp;rft.issue=5&amp;rft.pages=341&amp;rft.date=2010&amp;rft_id=info%3Adoi%2F10.2165%2F11536990-000000000-00000&amp;rft.aulast=Denis&amp;rft.aufirst=Alain&amp;rft.au=Mergaert%2C+Lut&amp;rft.au=Fostier%2C+Christel&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Explicit use of et al. (<a href=\"/wiki/Category:CS1_maint:_Explicit_use_of_et_al.\" title=\"Category:CS1 maint: Explicit use of et al.\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Arno, Peter S.; Bonuck, Karen; Davis, Michael (1995-01-01). \"Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act\". <i>The Milbank Quarterly</i>. <b>73</b> (2): 231\u2013252. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.2307/3350258\">10.2307/3350258</a>. <a href=\"/wiki/JSTOR\" title=\"JSTOR\">JSTOR</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.jstor.org/stable/3350258\">3350258</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Milbank+Quarterly&amp;rft.atitle=Rare+Diseases%2C+Drug+Development%2C+and+AIDS%3A+The+Impact+of+the+Orphan+Drug+Act&amp;rft.volume=73&amp;rft.issue=2&amp;rft.pages=231-252&amp;rft.date=1995-01-01&amp;rft_id=info%3Adoi%2F10.2307%2F3350258&amp;rft_id=%2F%2Fwww.jstor.org%2Fstable%2F3350258&amp;rft.aulast=Arno&amp;rft.aufirst=Peter+S.&amp;rft.au=Bonuck%2C+Karen&amp;rft.au=Davis%2C+Michael&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Technology-19\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Technology_19-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Technology_19-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Wechsler, Jill (July 2008). \"Celebrating 25 Years of Orphan Drugs\". <i>Pharmaceutical Technology</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmaceutical+Technology&amp;rft.atitle=Celebrating+25+Years+of+Orphan+Drugs&amp;rft.date=2008-07&amp;rft.au=Wechsler%2C+Jill&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\">Hadjivasiliou, Andreas (2015). <i>EvaluatePharma Orphan Drug Report 2015</i>. EvaulatePharma.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=EvaluatePharma+Orphan+Drug+Report+2015&amp;rft.pub=EvaulatePharma&amp;rft.date=2015&amp;rft.aulast=Hadjivasiliou&amp;rft.aufirst=Andreas&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Thomas, Katie (30 December 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2016/12/30/business/spinraza-price.html\">\"Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval\"</a>. New York Times<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">12 April</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Costly+Drug+for+Fatal+Muscular+Disease+Wins+F.D.A.+Approval&amp;rft.date=2016-12-30&amp;rft.aulast=Thomas&amp;rft.aufirst=Katie&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2016%2F12%2F30%2Fbusiness%2Fspinraza-price.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Carina Schey , Tsveta Milanova and Adam Hutchings (2011). <a rel=\"nofollow\" class=\"external text\" href=\"https://ojrd.biomedcentral.com/track/pdf/10.1186/1750-1172-6-62?site=ojrd.biomedcentral.com\">\"Estimating the budget impact of orphan medicines in Europe: 2010 - 2020\"</a>. <i>Orphanet Journal of Rare Diseases</i>. <b>6</b> (62). <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1186/1750-1172-6-62\">10.1186/1750-1172-6-62</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Orphanet+Journal+of+Rare+Diseases&amp;rft.atitle=Estimating+the+budget+impact+of+orphan+medicines+in+Europe%3A+2010+-+2020&amp;rft.volume=6&amp;rft.issue=62&amp;rft.date=2011&amp;rft_id=info%3Adoi%2F10.1186%2F1750-1172-6-62&amp;rft.au=Carina+Schey+%2C+Tsveta+Milanova+and+Adam+Hutchings&amp;rft_id=https%3A%2F%2Fojrd.biomedcentral.com%2Ftrack%2Fpdf%2F10.1186%2F1750-1172-6-62%3Fsite%3Dojrd.biomedcentral.com&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-meek-23\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-meek_23-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-meek_23-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Meekings, Kiran N.; Williams, Cory S. M.; Arrowsmith, John E. (2012-07-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencedirect.com/science/article/pii/S1359644612000529\">\"Orphan drug development: an economically viable strategy for biopharma R&amp;D\"</a>. <i>Drug Discovery Today</i>. <b>17</b> (13\u201314): 660\u2013664. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.drudis.2012.02.005\">10.1016/j.drudis.2012.02.005</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/22366309\">22366309</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drug+Discovery+Today&amp;rft.atitle=Orphan+drug+development%3A+an+economically+viable+strategy+for+biopharma+R%26D&amp;rft.volume=17&amp;rft.issue=13%E2%80%9314&amp;rft.pages=660-664&amp;rft.date=2012-07-01&amp;rft_id=info%3Adoi%2F10.1016%2Fj.drudis.2012.02.005&amp;rft_id=info%3Apmid%2F22366309&amp;rft.aulast=Meekings&amp;rft.aufirst=Kiran+N.&amp;rft.au=Williams%2C+Cory+S.+M.&amp;rft.au=Arrowsmith%2C+John+E.&amp;rft_id=http%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS1359644612000529&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kesselheim AS; Myers JA; Avorn J (2011-06-08). <a rel=\"nofollow\" class=\"external text\" href=\"https://dx.doi.org/10.1001/jama.2011.769\">\"CHaracteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer\"</a>. <i>JAMA</i>. <b>305</b> (22): 2320\u20132326. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1001/jama.2011.769\">10.1001/jama.2011.769</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0098-7484\">0098-7484</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/21642684\">21642684</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=CHaracteristics+of+clinical+trials+to+support+approval+of+orphan+vs+nonorphan+drugs+for+cancer&amp;rft.volume=305&amp;rft.issue=22&amp;rft.pages=2320-2326&amp;rft.date=2011-06-08&amp;rft.issn=0098-7484&amp;rft_id=info%3Apmid%2F21642684&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2011.769&amp;rft.au=Kesselheim+AS&amp;rft.au=Myers+JA&amp;rft.au=Avorn+J&amp;rft_id=https%3A%2F%2Fdx.doi.org%2F10.1001%2Fjama.2011.769&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-CBC_Crowe_2015-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-CBC_Crowe_2015_25-0\">^</a></b></span> <span class=\"reference-text\"><cite id=\"CITEREFCrowe2015\" class=\"citation\">Crowe, Kelly (25 June 2015), <a rel=\"nofollow\" class=\"external text\" href=\"http://www.cbc.ca/news/health/how-pharmaceutical-company-alexion-set-the-price-of-the-world-s-most-expensive-drug-1.3125251\">\"How pharmaceutical company Alexion set the price of the world's most expensive drug: Cost of one of world's most expensive drugs shrouded in corporate secrecy\"</a>, <i>CBC News</i><span class=\"reference-accessdate\">, retrieved <span class=\"nowrap\">25 June</span> 2015</span></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CBC+News&amp;rft.atitle=How+pharmaceutical+company+Alexion+set+the+price+of+the+world%27s+most+expensive+drug%3A+Cost+of+one+of+world%27s+most+expensive+drugs+shrouded+in+corporate+secrecy&amp;rft.date=2015-06-25&amp;rft.aulast=Crowe&amp;rft.aufirst=Kelly&amp;rft_id=http%3A%2F%2Fwww.cbc.ca%2Fnews%2Fhealth%2Fhow-pharmaceutical-company-alexion-set-the-price-of-the-world-s-most-expensive-drug-1.3125251&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Drummond_2007-26\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Drummond_2007_26-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Drummond_2007_26-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation\">Drummond MF, Grubert N. (2007), <i>International Trends in the Use of Health Economic Data</i>, Spectrum Report, Decision Resources, Waltham MA</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=International+Trends+in+the+Use+of+Health+Economic+Data&amp;rft.place=Waltham+MA&amp;rft.series=Spectrum+Report%2C+Decision+Resources&amp;rft.date=2007&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Uses authors parameter (<a href=\"/wiki/Category:CS1_maint:_Uses_authors_parameter\" title=\"Category:CS1 maint: Uses authors parameter\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-NICE_2010-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-NICE_2010_27-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp\">\"Measuring effectiveness and cost effectiveness: the QALY\"</a>. NICE. 20 April 2010<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">15 Jun</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Measuring+effectiveness+and+cost+effectiveness%3A+the+QALY&amp;rft.pub=NICE&amp;rft.date=2010-04-20&amp;rft_id=http%3A%2F%2Fwww.nice.org.uk%2Fnewsroom%2Ffeatures%2Fmeasuringeffectivenessandcosteffectivenesstheqaly.jsp&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-28\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making\">\"Guide to the methods of technology appraisal 2013\"</a>. NICE. 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">15 Jun</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Guide+to+the+methods+of+technology+appraisal+2013&amp;rft.pub=NICE&amp;rft.date=2013&amp;rft_id=https%3A%2F%2Fwww.nice.org.uk%2Farticle%2Fpmg9%2Fchapter%2F6-the-appraisal-of-the-evidence-and-structured-decision-making&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Eurohealth_2008-29\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Eurohealth_2008_29-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Eurohealth_2008_29-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Eurohealth_2008_29-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite id=\"CITEREFDrummond2008\" class=\"citation\">Drummond, Michael F (2008), \"Challenges in the economic evaluation of orphan drugs\", <i>Eurohealth</i>, World Health Organization, <b>14</b> (2): 16\u2013257</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Eurohealth&amp;rft.atitle=Challenges+in+the+economic+evaluation+of+orphan+drugs&amp;rft.volume=14&amp;rft.issue=2&amp;rft.pages=16-257&amp;rft.date=2008&amp;rft.aulast=Drummond&amp;rft.aufirst=Michael+F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-McCabe_2005-30\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-McCabe_2005_30-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-McCabe_2005_30-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">McCabe C, Claxton K, Tsuchiya A. (2005). \"Orphan drugs and the NHS\". <i>British Medical Journal</i>. <b>331</b> (4): 1016\u201319.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=British+Medical+Journal&amp;rft.atitle=Orphan+drugs+and+the+NHS&amp;rft.volume=331&amp;rft.issue=4&amp;rft.pages=1016-19&amp;rft.date=2005&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Uses authors parameter (<a href=\"/wiki/Category:CS1_maint:_Uses_authors_parameter\" title=\"Category:CS1 maint: Uses authors parameter\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-McCabe_2007-31\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-McCabe_2007_31-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-McCabe_2007_31-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-McCabe_2007_31-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">McCabe C, Tsuchiya A, Claxton K, Raftery J. (2007). \"Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al\". <i>International Journal of Technology Assessment in Health Care</i>. <b>23</b> (3): 397\u2013404. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1017/s0266462307071012\">10.1017/s0266462307071012</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Technology+Assessment+in+Health+Care&amp;rft.atitle=Assessing+the+economic+challenges+posed+by+orphan+drugs%3A+a+comment+on+Drummond+et+al.&amp;rft.volume=23&amp;rft.issue=3&amp;rft.pages=397-404&amp;rft.date=2007&amp;rft_id=info%3Adoi%2F10.1017%2Fs0266462307071012&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Uses authors parameter (<a href=\"/wiki/Category:CS1_maint:_Uses_authors_parameter\" title=\"Category:CS1 maint: Uses authors parameter\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-32\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-32\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Simoens, Steven (2011-06-17). <a rel=\"nofollow\" class=\"external text\" href=\"http://ojrd.biomedcentral.com/articles/10.1186/1750-1172-6-42\">\"Pricing and reimbursement of orphan drugs: the need for more transparency\"</a>. <i>Orphanet Journal of Rare Diseases</i>. <b>6</b> (1): 42. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1186/1750-1172-6-42\">10.1186/1750-1172-6-42</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3132155\">3132155</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/21682893\">21682893</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Orphanet+Journal+of+Rare+Diseases&amp;rft.atitle=Pricing+and+reimbursement+of+orphan+drugs%3A+the+need+for+more+transparency&amp;rft.volume=6&amp;rft.issue=1&amp;rft.pages=42&amp;rft.date=2011-06-17&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3132155&amp;rft_id=info%3Apmid%2F21682893&amp;rft_id=info%3Adoi%2F10.1186%2F1750-1172-6-42&amp;rft.aulast=Simoens&amp;rft.aufirst=Steven&amp;rft_id=http%3A%2F%2Fojrd.biomedcentral.com%2Farticles%2F10.1186%2F1750-1172-6-42&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NICE_2014-33\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-NICE_2014_33-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.nice.org.uk/news/press-and-media/nice-calls-for-a-new-approach-to-managing-the-entry-of-drugs-into-the-nhs\">\"NICE calls for a new approach to managing the entry of drugs into the NHS\"</a>, <i>NICE</i>, 18 September 2014<span class=\"reference-accessdate\">, retrieved <span class=\"nowrap\">29 June</span> 2015</span></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=NICE&amp;rft.atitle=NICE+calls+for+a+new+approach+to+managing+the+entry+of+drugs+into+the+NHS&amp;rft.date=2014-09-18&amp;rft_id=http%3A%2F%2Fwww.nice.org.uk%2Fnews%2Fpress-and-media%2Fnice-calls-for-a-new-approach-to-managing-the-entry-of-drugs-into-the-nhs&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AOrphan+drug\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Orphan_drug&amp;action=edit&amp;section=18\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<table role=\"presentation\" class=\"mbox-small plainlinks sistersitebox\" style=\"background-color:#f9f9f9;border:1px solid #aaa;color:#000\">\n<tbody><tr>\n<td class=\"mbox-image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/9/99/Wiktionary-logo-en-v2.svg/40px-Wiktionary-logo-en-v2.svg.png\" width=\"40\" height=\"40\" class=\"noviewer\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/9/99/Wiktionary-logo-en-v2.svg/60px-Wiktionary-logo-en-v2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/9/99/Wiktionary-logo-en-v2.svg/80px-Wiktionary-logo-en-v2.svg.png 2x\" data-file-width=\"512\" data-file-height=\"512\" /></td>\n<td class=\"mbox-text plainlist\">Look up <i><b><a href=\"https://en.wiktionary.org/wiki/Special:Search/orphan_drug\" class=\"extiw\" title=\"wiktionary:Special:Search/orphan drug\">orphan drug</a></b></i> in Wiktionary, the free dictionary.</td></tr></tbody></table>\n<table role=\"presentation\" class=\"mbox-small plainlinks sistersitebox\" style=\"background-color:#f9f9f9;border:1px solid #aaa;color:#000\">\n<tbody><tr>\n<td class=\"mbox-image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/30px-Commons-logo.svg.png\" width=\"30\" height=\"40\" class=\"noviewer\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/45px-Commons-logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/59px-Commons-logo.svg.png 2x\" data-file-width=\"1024\" data-file-height=\"1376\" /></td>\n<td class=\"mbox-text plainlist\">Wikimedia Commons has media related to <i><b><a href=\"https://commons.wikimedia.org/wiki/Category:Orphan_drugs\" class=\"extiw\" title=\"commons:Category:Orphan drugs\">Orphan drugs</a></b></i>.</td></tr></tbody></table>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.diahome.org\">Drug Information Association</a> (DIA)</li>\n<li>EVENT: <a rel=\"nofollow\" class=\"external text\" href=\"http://www.diahome.org/DIAHome/Education/FindEducationalOffering.aspx?productID=23774&amp;eventType=Meeting\">DIA/FDA Orphan Drug Designation Workshop November 2010</a></li>\n<li><a href=\"/wiki/European_Commission\" title=\"European Commission\">European Commission</a> - <a rel=\"nofollow\" class=\"external text\" href=\"http://ec.europa.eu/health/ph_threats/non_com/rare_6_en.htm\">The Orphan drugs strategy</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20071014211858/http://ec.europa.eu/enterprise/pharmaceuticals/register/orphreg.htm\">List of European Orphan Drugs</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/Overview/ucm119477.htm\">USA Food and Drug Administration: The Orphan Drug Act (as amended)</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm\">US FDA List of Orphan Designations and Approvals</a></li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw1228\nCached time: 20180906162559\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.580 seconds\nReal time usage: 0.702 seconds\nPreprocessor visited node count: 3092/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 86139/2097152 bytes\nTemplate argument size: 4598/2097152 bytes\nHighest expansion depth: 12/40\nExpensive parser function count: 4/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 47977/5000000 bytes\nNumber of Wikibase entities loaded: 1/400\nLua time usage: 0.278/10.000 seconds\nLua memory usage: 4.68 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  576.634      1 -total\n 48.91%  282.053      1 Template:Reflist\n 19.24%  110.918      5 Template:Citation_needed\n 15.37%   88.650      5 Template:Fix\n 11.92%   68.743     11 Template:Cite_journal\n 11.01%   63.513      7 Template:Cite_news\n  8.90%   51.294      8 Template:Citation\n  8.42%   48.576     12 Template:Category_handler\n  8.33%   48.029      6 Template:Delink\n  7.24%   41.729      1 Template:Commonscat\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:395889-0!canonical and timestamp 20180906162559 and revision id 858360579\n -->\n</div>"},"langlinks":[{"lang":"ar","url":"https://ar.wikipedia.org/wiki/%D8%AF%D9%88%D8%A7%D8%A1_%D9%8A%D8%AA%D9%8A%D9%85","langname":"Arabic","autonym":"\u0627\u0644\u0639\u0631\u0628\u064a\u0629","*":"\u062f\u0648\u0627\u0621 \u064a\u062a\u064a\u0645"},{"lang":"ca","url":"https://ca.wikipedia.org/wiki/F%C3%A0rmac_orfe","langname":"Catalan","autonym":"catal\u00e0","*":"F\u00e0rmac orfe"},{"lang":"de","url":"https://de.wikipedia.org/wiki/Orphan-Arzneimittel","langname":"German","autonym":"Deutsch","*":"Orphan-Arzneimittel"},{"lang":"el","url":"https://el.wikipedia.org/wiki/%CE%9F%CF%81%CF%86%CE%B1%CE%BD%CF%8C_%CF%86%CE%AC%CF%81%CE%BC%CE%B1%CE%BA%CE%BF","langname":"Greek","autonym":"\u0395\u03bb\u03bb\u03b7\u03bd\u03b9\u03ba\u03ac","*":"\u039f\u03c1\u03c6\u03b1\u03bd\u03cc \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03bf"},{"lang":"es","url":"https://es.wikipedia.org/wiki/Medicamento_hu%C3%A9rfano","langname":"Spanish","autonym":"espa\u00f1ol","*":"Medicamento hu\u00e9rfano"},{"lang":"fa","url":"https://fa.wikipedia.org/wiki/%D8%AF%D8%A7%D8%B1%D9%88%D9%87%D8%A7%DB%8C_%DA%A9%D9%85%E2%80%8C%DA%A9%D8%A7%D8%B1%D8%A8%D8%B1%D8%AF","langname":"Persian","autonym":"\u0641\u0627\u0631\u0633\u06cc","*":"\u062f\u0627\u0631\u0648\u0647\u0627\u06cc \u06a9\u0645\u200c\u06a9\u0627\u0631\u0628\u0631\u062f"},{"lang":"fr","url":"https://fr.wikipedia.org/wiki/M%C3%A9dicament_orphelin","langname":"French","autonym":"fran\u00e7ais","*":"M\u00e9dicament orphelin"},{"lang":"gl","url":"https://gl.wikipedia.org/wiki/Medicamento_orfo","langname":"Galician","autonym":"galego","*":"Medicamento orfo"},{"lang":"it","url":"https://it.wikipedia.org/wiki/Farmaci_orfani","langname":"Italian","autonym":"italiano","*":"Farmaci orfani"},{"lang":"he","url":"https://he.wikipedia.org/wiki/%D7%AA%D7%A8%D7%95%D7%A4%D7%94_%D7%99%D7%AA%D7%95%D7%9E%D7%94","langname":"Hebrew","autonym":"\u05e2\u05d1\u05e8\u05d9\u05ea","*":"\u05ea\u05e8\u05d5\u05e4\u05d4 \u05d9\u05ea\u05d5\u05de\u05d4"},{"lang":"nl","url":"https://nl.wikipedia.org/wiki/Weesgeneesmiddel","langname":"Dutch","autonym":"Nederlands","*":"Weesgeneesmiddel"},{"lang":"ja","url":"https://ja.wikipedia.org/wiki/%E5%B8%8C%E5%B0%91%E7%96%BE%E7%97%85%E7%94%A8%E5%8C%BB%E8%96%AC%E5%93%81","langname":"Japanese","autonym":"\u65e5\u672c\u8a9e","*":"\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1"},{"lang":"pl","url":"https://pl.wikipedia.org/wiki/Leki_sieroce","langname":"Polish","autonym":"polski","*":"Leki sieroce"},{"lang":"pt","url":"https://pt.wikipedia.org/wiki/Medicamento_%C3%B3rf%C3%A3o","langname":"Portuguese","autonym":"portugu\u00eas","*":"Medicamento \u00f3rf\u00e3o"},{"lang":"ru","url":"https://ru.wikipedia.org/wiki/%D0%9E%D1%80%D1%84%D0%B0%D0%BD%D0%BD%D1%8B%D0%B5_%D0%BF%D1%80%D0%B5%D0%BF%D0%B0%D1%80%D0%B0%D1%82%D1%8B","langname":"Russian","autonym":"\u0440\u0443\u0441\u0441\u043a\u0438\u0439","*":"\u041e\u0440\u0444\u0430\u043d\u043d\u044b\u0435 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u044b"},{"lang":"sl","url":"https://sl.wikipedia.org/wiki/Zdravilo_sirota","langname":"Slovenian","autonym":"sloven\u0161\u010dina","*":"Zdravilo sirota"},{"lang":"ta","url":"https://ta.wikipedia.org/wiki/%E0%AE%85%E0%AE%A8%E0%AE%BE%E0%AE%A4%E0%AF%88_%E0%AE%AE%E0%AE%B0%E0%AF%81%E0%AE%A8%E0%AF%8D%E0%AE%A4%E0%AF%81","langname":"Tamil","autonym":"\u0ba4\u0bae\u0bbf\u0bb4\u0bcd","*":"\u0b85\u0ba8\u0bbe\u0ba4\u0bc8 \u0bae\u0bb0\u0bc1\u0ba8\u0bcd\u0ba4\u0bc1"},{"lang":"uk","url":"https://uk.wikipedia.org/wiki/%D0%9E%D1%80%D1%84%D0%B0%D0%BD%D0%BD%D1%96_%D0%BF%D1%80%D0%B5%D0%BF%D0%B0%D1%80%D0%B0%D1%82%D0%B8","langname":"Ukrainian","autonym":"\u0443\u043a\u0440\u0430\u0457\u043d\u0441\u044c\u043a\u0430","*":"\u041e\u0440\u0444\u0430\u043d\u043d\u0456 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0438"},{"lang":"zh","url":"https://zh.wikipedia.org/wiki/%E5%AD%A4%E5%84%BF%E8%8D%AF","langname":"Chinese","autonym":"\u4e2d\u6587","*":"\u5b64\u513f\u836f"}],"categories":[{"sortkey":"","hidden":"","*":"CS1_maint:_BOT:_original-url_status_unknown"},{"sortkey":"","hidden":"","*":"CS1_maint:_Uses_authors_parameter"},{"sortkey":"","hidden":"","*":"CS1_maint:_Explicit_use_of_et_al."},{"sortkey":"Orphan Drug","hidden":"","*":"All_articles_with_unsourced_statements"},{"sortkey":"Orphan Drug","hidden":"","*":"Articles_with_unsourced_statements_from_July_2017"},{"sortkey":"Orphan Drug","hidden":"","*":"Articles_containing_potentially_dated_statements_from_2014"},{"sortkey":"Orphan Drug","hidden":"","*":"All_articles_containing_potentially_dated_statements"},{"sortkey":"Orphan Drug","hidden":"","*":"Articles_with_unsourced_statements_from_April_2017"},{"sortkey":"Orphan Drug","hidden":"","*":"Wikipedia_articles_needing_clarification_from_July_2015"},{"sortkey":" ","*":"Orphan_drugs"},{"sortkey":"Orphan Drug","*":"Biotechnology_law"},{"sortkey":"Orphan Drug","*":"Drug_discovery"},{"sortkey":"Orphan Drug","*":"Pharmaceuticals_policy"},{"sortkey":"Orphan Drug","*":"Health_economics"},{"sortkey":"Orphan Drug","*":"Life_sciences_industry"}],"links":[{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from July 2017"},{"ns":14,"exists":"","*":"Category:Articles containing potentially dated statements from 2014"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from April 2017"},{"ns":14,"exists":"","*":"Category:Wikipedia articles needing clarification from July 2015"},{"ns":14,"exists":"","*":"Category:CS1 maint: BOT: original-url status unknown"},{"ns":14,"exists":"","*":"Category:CS1 maint: Explicit use of et al."},{"ns":14,"exists":"","*":"Category:CS1 maint: Uses authors parameter"},{"ns":0,"exists":"","*":"AIDS"},{"ns":0,"exists":"","*":"Arthritis"},{"ns":0,"exists":"","*":"AstraZeneca"},{"ns":0,"exists":"","*":"Bis-choline tetrathiomolybdate"},{"ns":0,"exists":"","*":"Cancer treatment"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Committee on Orphan Medicinal Products"},{"ns":0,"exists":"","*":"Compound annual growth rate"},{"ns":0,"exists":"","*":"Cost-utility analysis"},{"ns":0,"exists":"","*":"Crown corporation"},{"ns":0,"exists":"","*":"Cystic fibrosis"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Dosing"},{"ns":0,"exists":"","*":"Drug Discovery Today"},{"ns":0,"exists":"","*":"Drug development"},{"ns":0,"exists":"","*":"Eculizumab"},{"ns":0,"exists":"","*":"European Commission"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"European Organization for Rare Diseases"},{"ns":0,"exists":"","*":"European Union"},{"ns":0,"exists":"","*":"FDA Consumer"},{"ns":0,"exists":"","*":"Familial hypercholesterolemia"},{"ns":0,"exists":"","*":"Glioma"},{"ns":0,"exists":"","*":"Global Genes Project"},{"ns":0,"exists":"","*":"HIV"},{"ns":0,"exists":"","*":"Idiopathic thrombocytopenic purpura"},{"ns":0,"exists":"","*":"International Standard Serial Number"},{"ns":0,"exists":"","*":"JSTOR"},{"ns":0,"exists":"","*":"Keck Graduate Institute"},{"ns":0,"exists":"","*":"Medical research"},{"ns":0,"exists":"","*":"Medication"},{"ns":0,"exists":"","*":"Multiple myeloma"},{"ns":0,"exists":"","*":"National Institute for Health and Care Excellence"},{"ns":0,"exists":"","*":"National Organization for Rare Disorders"},{"ns":0,"exists":"","*":"Office of Rare Diseases"},{"ns":0,"exists":"","*":"Orphan Drug Act"},{"ns":0,"exists":"","*":"Orphan Drug Act of 1983"},{"ns":0,"exists":"","*":"Orphan disease"},{"ns":0,"exists":"","*":"Patient Protection and Affordable Care Act"},{"ns":0,"exists":"","*":"Penicillamine"},{"ns":0,"exists":"","*":"Pharmaceutical company"},{"ns":0,"exists":"","*":"Pharmacodynamics"},{"ns":0,"exists":"","*":"Pharmacokinetics"},{"ns":0,"exists":"","*":"Phenylketonuria"},{"ns":0,"exists":"","*":"Profit margin"},{"ns":0,"exists":"","*":"Profit motive"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Public Health Service Act"},{"ns":0,"exists":"","*":"Public policy (law)"},{"ns":0,"exists":"","*":"Pulmozyme"},{"ns":0,"exists":"","*":"Quality-adjusted life year"},{"ns":0,"exists":"","*":"Rare Diseases Act of 2002"},{"ns":0,"exists":"","*":"Rare disease"},{"ns":0,"exists":"","*":"Rare diseases"},{"ns":0,"exists":"","*":"Rosuvastatin"},{"ns":0,"exists":"","*":"Snake venom"},{"ns":0,"exists":"","*":"Spinraza"},{"ns":0,"exists":"","*":"Statins"},{"ns":0,"exists":"","*":"Supplementary protection certificate"},{"ns":0,"exists":"","*":"Tax incentive"},{"ns":0,"exists":"","*":"The New York Times"},{"ns":0,"exists":"","*":"Thomson Reuters"},{"ns":0,"exists":"","*":"Tobramycin"},{"ns":0,"exists":"","*":"U.S. Food and Drug Administration"},{"ns":0,"exists":"","*":"United States"},{"ns":0,"exists":"","*":"United States Congress"},{"ns":0,"exists":"","*":"University of Minnesota"},{"ns":0,"exists":"","*":"Wilson's disease"},{"ns":0,"*":"Center for Orphan Drug Research"},{"ns":4,"exists":"","*":"Wikipedia:Citation needed"},{"ns":4,"exists":"","*":"Wikipedia:Please clarify"}],"templates":[{"ns":10,"exists":"","*":"Template:Citation needed"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:As of"},{"ns":10,"exists":"","*":"Template:DMCA"},{"ns":10,"exists":"","*":"Template:Dated maintenance category"},{"ns":10,"exists":"","*":"Template:FULLROOTPAGENAME"},{"ns":10,"exists":"","*":"Template:Ns has subpages"},{"ns":10,"exists":"","*":"Template:Rp"},{"ns":10,"exists":"","*":"Template:Quote"},{"ns":10,"exists":"","*":"Template:Quote/styles.css"},{"ns":10,"exists":"","*":"Template:Comma separated entries"},{"ns":10,"exists":"","*":"Template:If empty"},{"ns":10,"exists":"","*":"Template:Clarify"},{"ns":10,"exists":"","*":"Template:Fix-span"},{"ns":10,"exists":"","*":"Template:Replace"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Citation"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite book"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Wiktionary"},{"ns":10,"exists":"","*":"Template:Sister project"},{"ns":10,"exists":"","*":"Template:Side box"},{"ns":10,"exists":"","*":"Template:Commonscat"},{"ns":10,"exists":"","*":"Template:Commons category"},{"ns":10,"exists":"","*":"Template:Commons"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Ns has subpages"},{"ns":828,"exists":"","*":"Module:Separated entries"},{"ns":828,"exists":"","*":"Module:TableTools"},{"ns":828,"exists":"","*":"Module:If empty"},{"ns":828,"exists":"","*":"Module:String"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Side box"}],"images":["Lock-green.svg","Rosuvastatin-Formulae_V_1.png","Wiktionary-logo-en-v2.svg","Commons-logo.svg"],"externallinks":["http://info.evaluategroup.com/rs/evaluatepharmaltd/images/2014OD.pdf","https://web.archive.org/web/20121203212325/http://www.siope.eu/SIOPE-EU/English/SIOPE-EU/Advocacy-Activities/Rare-Diseases/page.aspx/148","http://www.prnewswire.com/news-releases/global-orphan-drug-market-to-reach-us-120-billion-by-2018-244195511.html","https://web.archive.org/web/20150513083426/http://thomsonreuters.com/content/dam/openweb/documents/pdf/pharma-life-sciences/white-paper/1001450.pdf","http://thomsonreuters.com/content/dam/openweb/documents/pdf/pharma-life-sciences/white-paper/1001450.pdf","http://www.drugdiscoverytoday.com/download/900","//doi.org/10.1016/j.drudis.2012.02.005","//www.ncbi.nlm.nih.gov/pubmed/22366309","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4405057","//doi.org/10.1002/wmh3.131","//www.ncbi.nlm.nih.gov/pubmed/25914853","http://www.fda.gov/Fdac/features/1999/399_orph.html","https://query.nytimes.com/gst/fullpage.html?sec=health&res=9C0CE4DF1F3EF933A05757C0A966958260","//www.ncbi.nlm.nih.gov/pubmed/16539081","http://www.medterms.com/script/main/art.asp?articlekey=11418","http://booksandjournals.brillonline.com/content/journals/10.1163/15718093-12341439","//doi.org/10.1163/15718093-12341439","http://www.pharmasentry.com/news/newsletter.cfm?linkid=CE077395-1372-54C2-61CFB42D06A278FB","http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?forceid=46273&next=bioWorldToday_article&search=1&prodID=4&htsid=0&htmax=237","//doi.org/10.2165/11536990-000000000-00000","//doi.org/10.2307/3350258","//www.jstor.org/stable/3350258","https://www.nytimes.com/2016/12/30/business/spinraza-price.html","https://ojrd.biomedcentral.com/track/pdf/10.1186/1750-1172-6-62?site=ojrd.biomedcentral.com","//doi.org/10.1186/1750-1172-6-62","http://www.sciencedirect.com/science/article/pii/S1359644612000529","https://dx.doi.org/10.1001/jama.2011.769","//doi.org/10.1001/jama.2011.769","//www.worldcat.org/issn/0098-7484","//www.ncbi.nlm.nih.gov/pubmed/21642684","http://www.cbc.ca/news/health/how-pharmaceutical-company-alexion-set-the-price-of-the-world-s-most-expensive-drug-1.3125251","http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp","https://www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making","//doi.org/10.1017/s0266462307071012","http://ojrd.biomedcentral.com/articles/10.1186/1750-1172-6-42","//doi.org/10.1186/1750-1172-6-42","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3132155","//www.ncbi.nlm.nih.gov/pubmed/21682893","http://www.nice.org.uk/news/press-and-media/nice-calls-for-a-new-approach-to-managing-the-entry-of-drugs-into-the-nhs","http://www.diahome.org","http://www.diahome.org/DIAHome/Education/FindEducationalOffering.aspx?productID=23774&eventType=Meeting","http://ec.europa.eu/health/ph_threats/non_com/rare_6_en.htm","https://web.archive.org/web/20071014211858/http://ec.europa.eu/enterprise/pharmaceuticals/register/orphreg.htm","http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/Overview/ucm119477.htm","http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm"],"sections":[{"toclevel":1,"level":"2","line":"Definition","number":"1","index":"1","fromtitle":"Orphan_drug","byteoffset":1269,"anchor":"Definition"},{"toclevel":1,"level":"2","line":"Global statistics","number":"2","index":"2","fromtitle":"Orphan_drug","byteoffset":2756,"anchor":"Global_statistics"},{"toclevel":1,"level":"2","line":"Effect on investment, sales and profit","number":"3","index":"3","fromtitle":"Orphan_drug","byteoffset":3832,"anchor":"Effect_on_investment,_sales_and_profit"},{"toclevel":1,"level":"2","line":"Legislation","number":"4","index":"4","fromtitle":"Orphan_drug","byteoffset":7736,"anchor":"Legislation"},{"toclevel":2,"level":"3","line":"United States","number":"4.1","index":"5","fromtitle":"Orphan_drug","byteoffset":9581,"anchor":"United_States"},{"toclevel":2,"level":"3","line":"European Union","number":"4.2","index":"6","fromtitle":"Orphan_drug","byteoffset":11443,"anchor":"European_Union"},{"toclevel":2,"level":"3","line":"Other countries","number":"4.3","index":"7","fromtitle":"Orphan_drug","byteoffset":13829,"anchor":"Other_countries"},{"toclevel":2,"level":"3","line":"Numbers of new drugs","number":"4.4","index":"8","fromtitle":"Orphan_drug","byteoffset":14288,"anchor":"Numbers_of_new_drugs"},{"toclevel":1,"level":"2","line":"Examples for selected diseases","number":"5","index":"9","fromtitle":"Orphan_drug","byteoffset":17908,"anchor":"Examples_for_selected_diseases"},{"toclevel":1,"level":"2","line":"Activism, research centers","number":"6","index":"10","fromtitle":"Orphan_drug","byteoffset":19331,"anchor":"Activism,_research_centers"},{"toclevel":1,"level":"2","line":"Cost","number":"7","index":"11","fromtitle":"Orphan_drug","byteoffset":20508,"anchor":"Cost"},{"toclevel":1,"level":"2","line":"Public-funding","number":"8","index":"12","fromtitle":"Orphan_drug","byteoffset":25146,"anchor":"Public-funding"},{"toclevel":2,"level":"3","line":"Evaluation criteria","number":"8.1","index":"13","fromtitle":"Orphan_drug","byteoffset":25165,"anchor":"Evaluation_criteria"},{"toclevel":2,"level":"3","line":"Abuse potential","number":"8.2","index":"14","fromtitle":"Orphan_drug","byteoffset":27988,"anchor":"Abuse_potential"},{"toclevel":2,"level":"3","line":"NICE","number":"8.3","index":"15","fromtitle":"Orphan_drug","byteoffset":29409,"anchor":"NICE"},{"toclevel":1,"level":"2","line":"See also","number":"9","index":"16","fromtitle":"Orphan_drug","byteoffset":30561,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"10","index":"17","fromtitle":"Orphan_drug","byteoffset":30687,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"11","index":"18","fromtitle":"Orphan_drug","byteoffset":30717,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Orphan drug","iwlinks":[{"prefix":"wiktionary","url":"https://en.wiktionary.org/wiki/Special:Search/orphan_drug","*":"wiktionary:Special:Search/orphan drug"},{"prefix":"commons","url":"https://commons.wikimedia.org/wiki/Category:Orphan_drugs","*":"commons:Category:Orphan drugs"}],"properties":[{"name":"defaultsort","*":"Orphan Drug"},{"name":"wikibase_item","*":"Q1367466"}]}}